99% Purity Lorlatinib Powder Pharmaceutical Grade Lorlatinib Powder Raw Lorlatinib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung-Lorlatinib
• Product Name: Lorlatinib
• Name: Lorlatinib Powder
• Appearance: White Powder
• Color: White Color
• Store: Cool and Dry
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anthelmintics
• Specific: COA
• Test Method: HPLC, UV
• Shelf Life: 2 Years
• CAS No.: 1454846-35-5
• Mf: C21h19fn6o2
• Density: 1.42-0.1 g/cm3
• Melting Point: 675.0-55.0
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi Xian
• Production Capacity: 5000kg/Month

Product Description

99% Purity Lorlatinib powder Pharmaceutical Grade Lorlatinib powder Raw Lorlatinib

Product Description

Product Details

Product Name	Lorlatinib
Appearance	White Powder
CAS No.	1454846-35-5
MF	C21H19FN6O2

Lorlatinib (PF-06463922) is a new drug under development for the sub-group of advanced non-small cell lung cancerwho are ALK or ROS1 positive and have already undergone gene treatment with drugs thatspecifically targetthis type of cancer.Lorlatinib is currently being evaluated in phase II clinical trials as an oral dose at 100 mg daily. If marketed it will becomean additional targeted treatment for this sub-group of ALKor ROS1 positive patients.

Application&Function

It is mainly targeted at patients with non-small cell lung cancer who are resistant to the first-generation ALK inhibitors crizotinib and resistant to the second-generation ALK inhibitors Ceritinib and Alectinib.
Laroratinib (PF-06463922) is an ALK inhibitor modified from Crizotinib, which entered clinical trials in 2014 for the treatment of Chemicalbook lung cancer.It is mainly targeted at patients with non-small cell lung cancer who are resistant to the first-generation ALK inhibitors crizotinib and resistant to the second-generation ALK inhibitors Ceritinib and Alectinib.

Specification